| 2025-12-10 |
详情>>
内部人交易：
VARKI PAUL等共交易4笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本1813.40万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-5.47美元,归母净利润-6453.9万美元,同比去年增长-30832.86%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-3.18美元,归母净利润-3391.4万美元,同比去年增长-48.57%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-1.25美元,归母净利润-1314.9万美元,同比去年增长89.16%
|
| 2025-05-01 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors nominated by our board of directors (the “Board”) and named herein to hold office for a one-year term until the 2026 Annual Meeting of Stockholders;
2.To approve, on a nonbinding advisory basis, a “Say-on-Pay” resolution regarding the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-7.94美元,归母净利润-3512.9万美元,同比去年增长-11.37%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.01美元,归母净利润21.00万美元,同比去年增长100.90%
|
| 2024-09-03 |
复牌提示：
2024-09-03 09:45:29 停牌，复牌日期 2024-09-03 09:55:29
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-24.11美元,归母净利润-2282.7万美元,同比去年增长-25.78%
|
| 2024-07-11 |
详情>>
业绩披露：
2024年一季报每股收益-141美元,归母净利润-1.21亿美元,同比去年增长-1118.38%
|
| 2024-06-27 |
股东大会：
将于2024-08-13召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors nominated by our board of directors (the “Board”) and named herein to hold office for a one-year term until the 2025 Annual Meeting of Stockholders;
2.To approve, for purposes of Rule 5635 of The Nasdaq Stock Market LLC (“Nasdaq”), the issuance of shares of the Company’s common stock (i) in exchange for the outstanding shares of the Company’s Series C Non-Voting Convertible Preferred Stock (the “Series C Preferred Stock”) and (ii) upon the exercise of the warrants to purchase shares of the Company’s common stock issued on March 28, 2024, and (iii) as possible payment for the milestone obligations to the former stockholders of AlmataBio, Inc. (“Almata”);
3.To approve the Avalo Therapeutics, Inc. Fourth Amended and Restated Equity Incentive Plan;
4.To approve the Avalo Therapeutics, Inc. Amended and Restated Employee Stock Purchase Plan;
5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
6.To approve the adjournment or postponement of the Annual Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2, 3, 4, and/or 5;
7.To conduct any other business properly brought before the Annual Meeting.
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-114美元,归母净利润-3154.4万美元,同比去年增长24.28%
|
| 2023-12-29 |
详情>>
拆分方案：
每240.0000合并分成1.0000股
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.96美元,归母净利润-2337.6万美元,同比去年增长26.60%
|
| 2023-10-19 |
股东大会：
将于2023-12-05召开股东大会
会议内容 ▼▲
- 1.To elect the five directors nominated by our board of directors (the “Board”) and named herein to hold office for a one-year term until the 2024 Annual Meeting of Stockholders;
2.To approve an amendment to our Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio of between 1-for-5 and 1-for-250 as determined by the Board;
3.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-1.41美元,归母净利润-1814.8万美元,同比去年增长48.20%
|
| 2022-07-08 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2022-04-25 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors nominated by our board of directors (the “Board”) and named herein to hold office for a one-year term until the 2023 Annual Meeting of Stockholders;
2.To approve an amendment to our Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio of between 1-for-5 and 1-for-20 as determined by our Board;
3.To approve, on a nonbinding advisory basis, a “Say-on-Pay” resolution regarding the compensation of our named executive officers;
4.To approve, on a nonbinding advisory basis, the frequency of future advisory votes on “Say-on-Pay” resolutions regarding the Company’s executive compensation;
5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors nominated by our board of directors (the “Board”) and named herein to hold office for a one-year term until the 2022 Annual Meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To conduct any other business properly brought before the Annual Meeting.
|
| 2020-04-28 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors nominated by our board of directors (the "Board") and named herein to hold office for a one-year term until the 2021 Annual Meeting of stockholders.
2.To approve the Cerecor Inc. Third Amended and Restated 2016 Equity Incentive Plan.
3.To conduct any other business properly brought before the meeting.
|
| 2019-06-19 |
股东大会：
将于2019-08-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors nominated by our board of directors (the "Board") and named herein to hold office for a one-year term until the 2020 Annual Meeting of stockholders.
2.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Certificate") to eliminate the provision requiring a super-majority stockholder vote to amend the Certificate.
3.To approve an amendment to the Certificate and our Second Amended and Restated Bylaws (the "Bylaws") to eliminate the provisions requiring a super-majority stockholder vote to amend the Bylaws.
4.To approve an amendment to our Certificate and Bylaws to allow stockholders to act by majority written consent as long as Armistice Capital, LLC owns at least 40% of our outstanding stock.
5.To approve, as required by NASDAQ Listing Rule 5635(d), the issuance of shares in excess of 20% to sellers of Ichorion stock following the achievement of certain earn-out thresholds.
6.To approve the Cerecor Inc. Second Amended and Restated 2016 Equity Incentive Plan.
7.To conduct any other business properly brought before the meeting.
|
| 2018-04-05 |
股东大会：
将于2018-05-15召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate”) and our amended and restated bylaws (the “Bylaws”) to declassify our board of directors (the “Board”).
2.If Proposal 1 to declassify the Board is approved, to elect the six directors nominated by the Board and named herein to hold office until the 2019 Annual Meeting of Stockholders.
3.If Proposal 1 to declassify the Board is not approved, to elect the one Class III nominee for director and named herein to hold office until the 2021 Annual Meeting of Stockholders.
4.To approve an amendment to the Certificate to eliminate the provision requiring a super-majority stockholder vote to amend the Certificate.
5.To approve an amendment to the Certificate and Bylaws to eliminate the provisions requiring a super-majority stockholder vote to amend the Bylaws.
6.To approve an amendment to our Certificate and Bylaws to allow stockholders to act by majority written consent as long as Armistice Capital LLC owns at least 40% of our outstanding stock.
7.To approve, as required by and in accordance with NASDAQ Listing Rule 5635(d), the issuance of an aggregate of 2,349,968 additional shares of the Company’s common stock pursuant to our November 17, 2017 agreements to acquire TRx Pharmaceuticals, LLC and its subsidiaries.
8.To approve the Cerecor Inc. Amended and Restated 2016 Equity Incentive Plan.
9.To conduct any other business properly brought before the meeting.
|
| 2017-05-23 |
股东大会：
将于2017-06-30召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named herein to hold office until the 2020 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To approve, as required by and in accordance with NASDAQ Listing Rules 5635(b) and (d), the issuance of up to an aggregate of 26,225,714 shares of the Company’s common stock, par value $0.001 per share, which represents greater than 19.99% of the Company’s outstanding common stock, consisting of :
i.11,940,000 shares of common stock issuable upon the conversion of 4,179 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share, sold pursuant to the Securities Purchase Agreement, dated April 27, 2017 (the “Purchase Agreement”), as set forth in further detail in the accompanying proxy statement;
ii.14,285,714 shares of common stock issuable upon the exercise of common stock warrants issued pursuant to the Purchase Agreement, as set forth in further detail in the accompanying proxy statement.
4.To approve a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board of Directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from one-for-two (1:2) to one-for-10 (1:10), inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board of Directors prior to the date of the 2018 Annual Meeting of Stockholders.
5.To approve a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, if and only if Proposal 4 is both approved and implemented, a reduction in the total number of authorized shares of the Company’s common stock as illustrated in the table under the caption “Effects of Authorized Shares Reduction” in the section of the accompanying proxy statement entitled “Approval of Reduction in the Number of Authorized Shares of Common Stock.”
6.To conduct any other business properly brought before the meeting.
|
| 2017-03-31 |
股东大会：
将于2017-05-12召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named herein to hold office until the 2020 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To conduct any other business properly brought before the meeting.
|
| 2016-04-08 |
股东大会：
将于2016-05-18召开股东大会
会议内容 ▼▲
- 1. To elect the two nominees for director named herein to hold office until the 2019 Annual Meeting of Stockholders.
2. To approve the Cerecor Inc. 2016 Equity Incentive Plan.
3. To approve the Cerecor Inc. Employee Stock Purchase Plan.
4. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016.
5. To conduct any other business properly brought before the meeting.
|